Rankings
▼
Calendar
MDGL Q4 2019 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$30M
Net Income
-$28M
EPS (Diluted)
$-1.80
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$12M
Free Cash Flow
-$12M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$442M
Total Liabilities
$25M
Stockholders' Equity
$417M
Cash & Equivalents
$47M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$25,000
+100.0%
Operating Income
-$30M
-$14M
-107.2%
Net Income
-$28M
-$11M
-141.7%
← FY 2019
All Quarters
Q1 2020 →